Revenue Recognition and Contractual Adjustments (Tables)

3 Months Ended

Mar. 31, 2020

Revenue from Contract with Customer [Abstract]

Summary of Contract Assets and Liabilities

The following table summarizes the values of contract assets, capitalized commissions and contract liabilities as of March 31, 2020 and December 31, 2019 (in thousands):


	March 31, 2020		December 31, 2019
Current pharma contract assets ⁽¹⁾	$	1,127	$	1,000
Long-term pharma contract assets ⁽²⁾	199		153
Total pharma contract assets	$	1,326	$	1,153


Current pharma capitalized commissions ⁽¹⁾	$	141	$	133
Long-term pharma capitalized commissions ⁽²⁾	761		798
Total pharma capitalized commissions	$	902	$	931


Current pharma contract liabilities	$	2,974	$	1,610
Long-term pharma contract liabilities ⁽³⁾	526		1,171
Total pharma contract liabilities	$	3,500	$	2,781

⁽¹⁾ Current pharma contract assets and Current pharma capitalized commissions are classified as “Other current assets” on the Consolidated Balance Sheets.

⁽²⁾ Long-term pharma contract assets and Long-term pharma capitalized commissions are classified as “Other assets” on the Consolidated Balance Sheets.

(3) Long-term pharma contract liabilities are classified as “Other long-term liabilities” on the Consolidated Balance Sheets.

Summary of Disaggregation of Revenue

The following table details the disaggregation of revenue for both the Clinical and Pharma Services Segments (in thousands):


	Three Months Ended March 31,
	2020		2019
Clinical Services:
Client direct billing	$	54,292	$	49,756
Commercial Insurance	21,993		20,433
Medicare and Medicaid	16,483		15,793
Self-Pay	214		228
Total Clinical Services	$	92,982	$	86,210
Pharma Services:	13,048		9,367
Total Revenue	$	106,030	$	95,577